NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-OD-22-005 from the NIH Guide for Grants and Contracts
Notice of Clarification of Offeror Responsibilities Regarding Contract to Protocol Congruence Review
Notice NOT-OD-22-006 from the NIH Guide for Grants and Contracts
Notice NOT-AI-22-008 from the NIH Guide for Grants and Contracts
Notice NOT-AI-21-080 from the NIH Guide for Grants and Contracts
Notice NOT-AI-21-081 from the NIH Guide for Grants and Contracts
Notice NOT-DA-21-089 from the NIH Guide for Grants and Contracts
Notice NOT-CA-22-002 from the NIH Guide for Grants and Contracts
Notice NOT-DK-21-015 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-NS-21-025 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIH Blueprint for Neuroscience Research R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development. This FOA solicits Research Education Grant (R25) applications to develop and implement short courses on neurotherapeutics development for academic neuroscientists. The short courses should provide participants with a sufficient overview of the neurotherapeutics development process to (1) understand the steps required for therapeutics development, (2) anticipate and overcome common challenges in the process, and (3) interact effectively with collaborators who have expertise in various aspects of therapeutics development. The short courses should primarily target independent academic neuroscience researchers and senior post-doctoral fellows interested in incorporating treatment development into their research programs.
Notice NOT-DA-21-086 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AI-21-070 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support discovery and design of novel Group A Streptococcus (GAS) vaccine candidates and their advancement into preclinical evaluation for broad protection against GAS infections.
Notice NOT-OD-22-010 from the NIH Guide for Grants and Contracts
Notice NOT-HL-23-002 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AT-22-001 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages UG3/UH3 phased cooperative research applications to conduct efficient, large-scale pragmatic trials or implementation studies that focus on improving health outcomes for underserved US patient populations. Awards made under this FOA will initially support a one-year milestone-driven planning phase (UG3), with possible transition to an implementation phase (UH3). UG3 projects that have met the scientific milestone and feasibility requirements may transition to the UH3 phase. The UG3/UH3 application must be submitted as a single application, following the instructions described in this FOA. The overall goal of this initiative is to support the "real world" assessment of health care strategies and clinical practices and procedures in health care systems (HCS) that lead to improved care for underserved populations; who have suffered a disproportionate disease burden in the US. Results from the pragmatic studies supported by this FOA should inform policy makers, payers, doctors and patients across diverse patient care settings. This FOA requires that the intervention under study be embedded into health care delivery system, real world settings. Studies can propose to integrate multi-modal or multiple interventions that have demonstrated efficacy into HCS; or implement HCS changes to improve adherence to evidence-based guidelines. Trials or studies should be conducted across three or more health care systems (HCS) that provide care to underserved patient populations; and will become part of and work with the NIH HCS Research Collaboratory. The NIH HCS Research Collaboratory Program has established a Collaboratory Coordinating Center (CCC) that is providing national leadership and technical expertise in all aspects of research with HCS (See Companion FOA).
Funding Opportunity RFA-OH-22-003 from the NIH Guide for Grants and Contracts. The purpose of this program is to support NIOSH TPGs, to address the burden of OSH in the United States by providing state-of-the-art training for the next generation of leaders in OSH practice and research.
Funding Opportunity RFA-DK-21-029 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for Diabetes Research Centers that are designed to support and enhance the national research effort in diabetes, its complications, and related endocrine and metabolic diseases. Diabetes Research Centers support two primary research-related activities: Research Core services and a Pilot and Feasibility (P and F) program. All activities pursued by Diabetes Research Centers are designed to enhance the efficiency, productivity, effectiveness, and multidisciplinary nature of research in Diabetes Research Center topic areas. The NIDDK Diabetes Research Centers program in 2021 consists of 16 Centers each located at outstanding research institutions with documented programs of excellence in diabetes-related research. General information about the NIDDK Diabetes Research Centers program may be found at www.diabetescenters.org (http://www.diabetescenters.org).
Funding Opportunity PAR-22-048 from the NIH Guide for Grants and Contracts. There is consensus that environmental toxicants are a risk factor for AD/ADRD, but causality has been largely elusive. While human studies demonstrating an association of AD/ADRD with toxicant exposures are relatively abundant, there is a clear unmet need for more mechanistic research to support or refute the clinical relevance and the biological plausibility of an impact on disease initiation, progression, or modification. This is especially important for understanding the potentially modifiable causes of racial and socioeconomic inequities. The RFA will encourage neuroscientists to conduct mechanistic AD/ADRD research on the actions of neurotoxicants on the nervous system. The scope of research includes but is not limited to in silico modeling, in vitro assay development to correlate chemical exposure to AD/ADRD biology, and in vivo studies on the modification of known AD/ADRD targets by neurotoxicants of concern, and conversely, whether known targets for these neurotoxins play a role in the etiology of AD/ADRD. The development and validation of neuropathological, neurophysiological, and neurobehavioral animal models that simulate potential toxicant exposures in humans would be one goal, and when possible, these studies will include comparisons of exposures across the lifespan.
Notice NOT-MH-22-010 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-HD-22-021 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) invites applications from institutions/organizations interested in participating with the NICHD in an ongoing multicenter clinical program, the Pelvic Floor Disorders Network, which is designed to study clinical and health aspects of pelvic floor disorders in adult women.
Funding Opportunity RFA-HD-22-022 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) invites applications from institutions/organizations to participate with the NICHD as the Data Coordinating Center in an ongoing multicenter clinical program, the Pelvic Floor Disorders Network, designed to study clinical and health aspects of pelvic floor disorders in women.